Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

Re-Vana Therapeutics is based in Belfast, Northern Ireland and Boehringer Ingelheim is headquartered in Ingelheim, Germany. Image credit: ©NAMPIX – stock.adobe.com

In a press release, Re-Vana Therapeutics and Boehringer Ingelheim announced a $1 billion collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.

The key points of the agreement listed in the press release are:

• Up to three development programmes annually leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.
• The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programmes, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval and global commercialisation of the products.
• The terms of the agreement grant Boehringer Ingelheim target exclusivity and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with the total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.

Re-Vana’s drug delivery technology is designed to release slowly over 6 to 12 months, aiming to drastically reduce injection frequency. Lowering the treatment burden could lead to higher treatment compliance and potentially result in better therapeutic outcomes.

The press release noted that Re-Vana is not just a platform or drug delivery company. It is developing internal assets: a 6-month sustained-release aflibercept and a 6-month bio specific—both photo-crosslinked bio-erodible, and delivered in the clinic (non-surgical).

Nedim Pipic, Global Head of Mental Health, Eye Health, and Emerging Areas at Boehringer Ingelheim, commented, “We’re looking forward to team[ing] up with Re-Vana to push the boundaries of what’s possible in eye health. Together, we want to tackle the limits of today’s treatments—aiming to help people keep their sight with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients."

According to Michael O’Rourke, Re-Vana Chief Executive Officer, “The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana. By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.”

Re-Vana Therapeutics Ltd originated from Queen’s University Belfast in 2016 and is based in Belfast, Northern Ireland. It is a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida, and includes venture partnerships with US ophthalmic investors (Visionary Ventures, ExSight Ventures, InFocus Capital Partners) and UK investors (QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers). Boehringer Ingelheim is headquartered in Ingelheim, Germany, with 54,500 employees serving over 130 markets.

Reference

1. Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies. Press release. Re-Vana Therapeutics. Published July 28, 2025. Accessed July 28, 2025. https://www.revanatx.com/boehringer-ingelheim-and-re-vana-therapeutics-announce-strategic-collaboration-to-develop-long-acting-ophthalmic-therapies/